A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jan 2025 Status changed to completed, according to a Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics media release.
13 Jan 2025 According to a Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Media Release, the company plans to share these at an upcoming scientific conference.
13 Jan 2025 Primary endpoint has been met. (Percentage change in body weight), according to the Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com